Spiroheptane salicylamides and related compounds as inhibitors of rock

US10611776B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Leon M. Smith, II · Raritan, US
• Vladimir Ladziata · Ewing, US
• Indawati De Lucca · Pennington, US
• Donald J. P. Pinto · Nazareth, US
• Michael J. Orwat · New Hope, US
• Andrew K. Dilger · Princeton, US
• Kumar Balashanmuga Pabbisetty · Piscataway, US
• Wu-Der Yang · Taoyuan, TW
• Scott A. Shaw · Lawrence, US
• Peter W. Glunz · Wilmington, US
• Manoranjan Panda · Survanagiri, IN

Key dates

• Filing date: Jan 13, 2017
• Grant date: Apr 7, 2020
• Expiry date: Jan 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.